Common Stock, par value $0.00033 per share
- Symbol
- PDSB
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
PDS Biotechnology Corporation
PDSBNASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operation and Financial Condition. On August 13, 2026, PDS Biotechnology Corporation (the “Company”) issued a press release announcing a business update and its financial results for the quarter ended June 30, 2026. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1.…
Press release in this filing
PDS Biotech Reports Second Quarter 2026 Financial Results →Company context
We are a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer and infectious disease immunotherapies based on our Versamune® T cell activator and Versamune® in combination with our interleukin 12 (IL-12) fused anti-body drug conjugate (ADC), PDS01ADC. In addition, we are developing the Infectimune® T cell-activator in infectious diseases.
Current securities
Registered securities in this filing
PDS BIOTECHNOLOGY CORPORATION · 8-K · Filed 2026-08-13
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operation and Financial Condition.
On August 13, 2026, PDS Biotechnology Corporation (the “Company”) issued a press release announcing a business
update and its financial results for the quarter ended June 30, 2026. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1.
In accordance with General Instruction B.2 of Form 8-K, the information set forth in this Current Report on Form
8-K (including Exhibit 99.1) is deemed to be “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of the
section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Filed exhibits (1)
EX-99.1 2 ef20080122_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 PDS Biotech Reports Second Quarter 2026 Financial Results PRINCETON, N.J., August 13, 2026 -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer, today provided a business and clinical programs update and reported financial results for the quarter ended June 30, 2026. Clinical and Corporate Update Announced publication of positive clinical and immunological biomarker data from Stage 1 of the NCI-led metastatic colorectal cancer (mCRC) Phase 2, open-label, single-center, non-randomized clinical trial evaluating PDS0301 (formerly PDS01ADC), the Company’s tumor-targeted IL-12 immunocytokine. The clinical trial results, published in the March 2026 issue of the Journal of Clinical Oncology (JCO) Oncology Advances, included: ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── o Objective response rate …
Open exhibit ↗